Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Metastatic Uveal Melanoma
NCT05282901Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in Uveal melanoma (UM), sponsored by Institut Curie. Started Jul 2022; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05282901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282901.